It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Under physiological conditions, a finely tuned system of cellular adaptation allows the intestinal mucosa to maintain the gut barrier function while avoiding excessive immune responses to non-self-antigens from dietary origin or from commensal microbes. This homeostatic function is compromised in cystic fibrosis (CF) due to loss-of-function mutations in the CF transmembrane conductance regulator (CFTR). Recently, we reported that mice bearing defective CFTR are abnormally susceptible to a celiac disease-like enteropathy, in thus far that oral challenge with the gluten derivative gliadin elicits an inflammatory response. However, the mechanisms through which CFTR malfunction drives such an exaggerated response to dietary protein remains elusive. Here we demonstrate that the proteostasis regulator/transglutaminase 2 (TGM2) inhibitor cysteamine restores reduced Beclin 1 (BECN1) protein levels in mice bearing cysteamine-rescuable F508del-CFTR mutant, either in homozygosis or in compound heterozygosis with a null allele, but not in knock-out CFTR mice. When cysteamine restored BECN1 expression, autophagy was increased and gliadin-induced inflammation was reduced. The beneficial effects of cysteamine on F508del-CFTR mice were lost when these mice were backcrossed into a Becn1 haploinsufficient/autophagy-deficient background. Conversely, the transfection-enforced expression of BECN1 in human intestinal epithelial Caco-2 cells mitigated the pro-inflammatory cellular stress response elicited by the gliadin-derived P31–43 peptide. In conclusion, our data provide the proof-of-concept that autophagy stimulation may mitigate the intestinal malfunction of CF patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 San Raffaele Scientific Institute, European Institute for Research in Cystic Fibrosis, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
2 San Raffaele Scientific Institute, European Institute for Research in Cystic Fibrosis, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884); University of Eastern Piedmont, Department of Health Sciences, Novara, Italy (GRID:grid.16563.37) (ISNI:0000000121663741)
3 Federico II University Naples, Regional Cystic Fibrosis Center, Pediatric Unit, Department of Translational Medical Sciences, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X)
4 University of Rome “Tor Vergata”, Department of Biology, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
5 Istituto Superiore di Sanità, Department of Food Safety, Nutrition and Veterinary Public Health, Roma, Italy (GRID:grid.416651.1) (ISNI:0000 0000 9120 6856)
6 Fondazione IRCCS Policlinico San Matteo, Dipartimento di Pediatria, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)
7 University of Perugia, Department of Experimental Medicine, Perugia, Italy (GRID:grid.9027.c) (ISNI:0000 0004 1757 3630)
8 Institute of Citology, Gene Expression Laboratory, Saint-Petersburg, Russia (GRID:grid.9027.c)
9 Centre de Recherche des Cordeliers, Equipe11 labellisée Ligue Nationale contrele Cancer, Paris, France (GRID:grid.417925.c); INSERM U1138, Centre de Recherche des Cordeliers, Paris, France (GRID:grid.417925.c); Université Paris Descartes, Paris, France (GRID:grid.10992.33) (ISNI:0000 0001 2188 0914); Institut Gustave Roussy, Metabolomics and Cell Biology Platforms, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Hôpital Européen Georges Pompidou, AP-HP, Pôle de Biologie, Paris, France (GRID:grid.414093.b); Chinese Academy of Sciences, Suzhou Institute for Systems Biology, Suzhou, China (GRID:grid.9227.e) (ISNI:0000000119573309); Karolinska University Hospital, Karolinska Institute, Department of Women’s and Children’s Health, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)